Study Shows Empagliflozin May Not Make Much of a Difference for Chronic Kidney Disease
While the new EMPA-KIDNEY study showed positive results for empagliflozin as a treatment for kidney disease, the findings were simply of “lower risk” of “disease progression” or “death” than the placebo group, which indicates that the use of this product for treating kidney disease may not be all that effective.
Read more
